Anti-severe acute respiratory syndrome coronavirus 2 spike receptor-binding domain antibody levels in patients with systemic lupus erythematosus based on vaccination status and related factors in Indonesia.

IF 2.1 Q4 IMMUNOLOGY

Clinical and Experimental Vaccine Research Pub Date : 2024-10-01 Epub Date: 2024-10-31 DOI:10.7774/cevr.2024.13.4.348

Laniyati Hamijoyo, Patrick Philo, Daniel Setiawan Nathan, Marita Restie Tiara, Sofie Razyanti Mardiana, Evan Susandi, Nadia Gita Ghassani, Bachti Alisjahbana

{"title":"Anti-severe acute respiratory syndrome coronavirus 2 spike receptor-binding domain antibody levels in patients with systemic lupus erythematosus based on vaccination status and related factors in Indonesia.","authors":"Laniyati Hamijoyo, Patrick Philo, Daniel Setiawan Nathan, Marita Restie Tiara, Sofie Razyanti Mardiana, Evan Susandi, Nadia Gita Ghassani, Bachti Alisjahbana","doi":"10.7774/cevr.2024.13.4.348","DOIUrl":null,"url":null,"abstract":"Purpose: We aim to analyze the proportion and level of coronavirus disease 2019 (COVID-19) seropositivity in patients with systemic lupus erythematosus (SLE) and explore factors associated with lower anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike receptor-binding domain (S-RBD) antibody levels.Materials and methods: A cross-sectional study involving patients with SLE was conducted. We included those aged 18-60 years, either unvaccinated or had received inactivated vaccine (CoronaVac; Sinovac Biotech Ltd., China). Furthermore, participants were tested for anti-SARS-CoV-2 S-RBD antibody levels and SARS-CoV-2 surrogate virus neutralization test, and comparative test analysis was employed.Results: This study included 159 subjects of whom 92 and 67 were SLE subjects and controls, respectively. Significantly higher seropositive results were noted in patients with SLE receiving vaccine (96.9% versus 3.1%). Unvaccinated SLE patients receiving cyclophosphamide (CYC) had higher anti-RBD levels compared to unvaccinated SLE patients not receiving CYC (23.81 [interquartile range (IQR), 2.26-78.85] versus 2.13 [IQR, 0.1-12.5]), whereas vaccinated SLE patients receiving CYC had lower anti-RBD levels compared to vaccinated SLE patients not receiving CYC (15.5 [IQR, 6.62-35.09] and 69.77 [IQR, 17.48-201]). In the vaccinated SLE group, a lower value of anti-SARS-CoV-2 RBD antibody levels was observed in patients receiving mycophenolate mofetil and those with chronic kidney disease. No correlation was noted between disease activity and organ involvement with lower antibody response.Conclusion: The increase in COVID-19 antibody levels in patients with SLE may be affected by exposure to hospital settings and vaccine. Furthermore, CYC treatment is associated with lower antibody response after receiving vaccine.","PeriodicalId":51768,"journal":{"name":"Clinical and Experimental Vaccine Research","volume":"13 4","pages":"348-358"},"PeriodicalIF":2.1000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11543787/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Vaccine Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.7774/cevr.2024.13.4.348","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/31 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: We aim to analyze the proportion and level of coronavirus disease 2019 (COVID-19) seropositivity in patients with systemic lupus erythematosus (SLE) and explore factors associated with lower anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike receptor-binding domain (S-RBD) antibody levels.

Materials and methods: A cross-sectional study involving patients with SLE was conducted. We included those aged 18-60 years, either unvaccinated or had received inactivated vaccine (CoronaVac; Sinovac Biotech Ltd., China). Furthermore, participants were tested for anti-SARS-CoV-2 S-RBD antibody levels and SARS-CoV-2 surrogate virus neutralization test, and comparative test analysis was employed.

Results: This study included 159 subjects of whom 92 and 67 were SLE subjects and controls, respectively. Significantly higher seropositive results were noted in patients with SLE receiving vaccine (96.9% versus 3.1%). Unvaccinated SLE patients receiving cyclophosphamide (CYC) had higher anti-RBD levels compared to unvaccinated SLE patients not receiving CYC (23.81 [interquartile range (IQR), 2.26-78.85] versus 2.13 [IQR, 0.1-12.5]), whereas vaccinated SLE patients receiving CYC had lower anti-RBD levels compared to vaccinated SLE patients not receiving CYC (15.5 [IQR, 6.62-35.09] and 69.77 [IQR, 17.48-201]). In the vaccinated SLE group, a lower value of anti-SARS-CoV-2 RBD antibody levels was observed in patients receiving mycophenolate mofetil and those with chronic kidney disease. No correlation was noted between disease activity and organ involvement with lower antibody response.

Conclusion: The increase in COVID-19 antibody levels in patients with SLE may be affected by exposure to hospital settings and vaccine. Furthermore, CYC treatment is associated with lower antibody response after receiving vaccine.

查看原文本刊更多论文

印度尼西亚系统性红斑狼疮患者的抗严重急性呼吸系统综合征冠状病毒 2 尖峰受体结合域抗体水平，基于疫苗接种状况和相关因素。

目的：我们旨在分析系统性红斑狼疮（SLE）患者中2019年冠状病毒病（COVID-19）血清阳性的比例和水平，并探讨与抗严重急性呼吸系统综合征冠状病毒2（SARS-CoV-2）尖峰受体结合域（S-RBD）抗体水平较低相关的因素：进行了一项涉及系统性红斑狼疮患者的横断面研究。研究对象包括年龄在 18-60 岁之间、未接种疫苗或已接种灭活疫苗（CoronaVac；中国华卫生物科技有限公司）的患者。此外，我们还对参与者进行了抗SARS-CoV-2 S-RBD抗体水平检测和SARS-CoV-2替代病毒中和试验，并采用了比较试验分析：本研究共纳入 159 名受试者，其中系统性红斑狼疮受试者和对照组分别为 92 人和 67 人。接种疫苗的系统性红斑狼疮患者血清阳性率明显更高（96.9% 对 3.1%）。与未接种疫苗、接受环磷酰胺（CYC）治疗的系统性红斑狼疮患者相比，未接种疫苗、未接受环磷酰胺治疗的系统性红斑狼疮患者的抗 RBD 水平更高（23.81 [四分位距（IQR），2.26-78.85] 对 2.13 [四分位距（IQR），0.1]）。13[IQR，0.1-12.5]），而与未接种 CYC 疫苗的系统性红斑狼疮患者相比，接种 CYC 疫苗的系统性红斑狼疮患者的抗 RBD 水平较低（分别为 15.5 [IQR，6.62-35.09] 和 69.77 [IQR，17.48-201]）。在接种疫苗的系统性红斑狼疮患者组中，接受霉酚酸酯治疗的患者和患有慢性肾病的患者的抗 SARS-CoV-2 RBD 抗体水平较低。结论：COVID-19 抗体水平的升高与疾病活动性和器官受累与较低的抗体反应之间没有相关性：结论：系统性红斑狼疮患者 COVID-19 抗体水平的升高可能受到医院环境和疫苗暴露的影响。结论：系统性红斑狼疮患者 COVID-19 抗体水平的升高可能会受到医院环境和疫苗的影响。此外，CYC 治疗与接种疫苗后较低的抗体反应有关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical and Experimental Vaccine Research IMMUNOLOGY-

CiteScore

3.70

自引率

3.70%

发文量

审稿时长

8 weeks

期刊介绍： Clin Exp Vaccine Res, the official English journal of the Korean Vaccine Society, is an international, peer reviewed, and open-access journal. It covers all areas related to vaccines and vaccination. Clin Exp Vaccine Res publishes editorials, review articles, special articles, original articles, case reports, brief communications, and correspondences covering a wide range of clinical and experimental subjects including vaccines and vaccination for human and animals against infectious diseases caused by viruses, bacteria, parasites and tumor. The scope of the journal is to disseminate information that may contribute to elaborate vaccine development and vaccination strategies targeting infectious diseases and tumors in human and animals. Relevant topics range from experimental approaches to (pre)clinical trials for the vaccine research based on, but not limited to, basic laboratory, translational, and (pre)clinical investigations, epidemiology of infectious diseases and progression of all aspects in the health related issues. It is published printed and open accessed online issues (https://ecevr.org) two times per year in 31 January and 31 July. Clin Exp Vaccine Res is linked to many international databases and is made freely available to institutions and individuals worldwide